Global Cystic Fibrosis Therapeutics Market – Market Forecast, Market Trend, Market Research And Opportunity, Size And Share – 2014-2027


Cystic fibrosis (CF), additionally referred to as chromosome recessive disorder. The incidence of malady leads to thick and viscous secretions that causes a life threatening impact on the lungs, the pancreas, liver, and intestine, and also blocks the exocrine gland protein actions on the body. Cystic fibrosis is caused by mutation in the gene.

The global Cystic Fibrosis Therapeutics Market are expected to grow at a CAGR of 16.8% during the analysis period, 2017-2027

Market Dynamics


  • favorable initiatives taken by regional and national nonprofit organizations
  • rising prevalence of CF


  • Stringent regulatory guidelines
  • Unfavorable drug price control policies

Report Key Benefits


Market Segments

By Route of Administration

  • Oral drugs
  • Inhaled drugs

By Drug class

  • Pancreatic enzyme supplements
  • Bronchodilators
  • CFTR modulators
  • Mucolytics

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Brazil
    • Argentina
    • South Africa
    • Middle East
    • Rest of LAMEA

Company Profiles

  • AbbVie Inc
  • Gilead
  • Vertex Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co. Inc.
  • AstraZeneca
  • Hoffmann-La Roche Ltd
  • Novartis AG

Target Audience

  • Cystic Fibrosis Therapeutics drugs manufacturing companies
  • Service providers, dealers, distributors, and suppliers of Cystic Fibrosis Therapeutics drugs.
  • Healthcare institutes
  • Research institutes, associations and academicians
  • Market research and consulting firms
Place an Order


Looking for a Market Analysis Report?